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During infection in mammals, the protozoan parasite
Trypanosoma brucei transforms from a proliferative
bloodstream form to a quiescent form that is pre-
adapted to host transition. AMP analogs are known
to induce quiescence and also inhibit TbTOR4. To
examine the role of AMP-activated kinase (AMPK)
in the regulation of this developmental transition,
we characterized trypanosome TbAMPK com-
plexes. Expression of a constitutively active AMPKa1
induces quiescence of the infective form, and
TbAMPKa1 phosphorylation occurs during differen-
tiation of wild-type pleomorphic trypanosomes to
the quiescent stumpy form in vivo. Compound C, a
well-known AMPK inhibitor, inhibits parasite differ-
entiation in mice. We also provide evidence linking
oxidative stress to TbAMPKa1 activation and quies-
cent differentiation, suggesting that TbAMPKa1
activation balances quiescence, proliferation, and
differentiation.INTRODUCTION
All living organisms must adapt and respond to diverse environ-
mental conditions, including nutritional and energetic stress
(Fontana et al., 2010). Notably, protozoan parasites undergo
developmental transitions in response to changing environ-
mental conditions. Specifically, they ensure their own survival
by sensing and responding to the availability of nutrients in the
host environment (Goldenberg and Avila, 2011). Trypanosoma
brucei is an extracellular parasite that causes sleeping sickness.
Its life cycle alternates between a mammalian host and an
arthropod vector, the tsetse fly. In the mammalian host, and in
accordance with the emergence of high parasitemia, the blood-
stream form can fluctuate between a proliferative slender form
and a quiescent stumpy form, presumably to avoid damage to
the host (Fenn andMatthews, 2007; Turner et al., 1995). The tran-
sition between forms ismediated by quorum sensing in response
to the stumpy induction factor (SIF), a chemically uncharacter-
ized signal secreted by trypanosomes (Vassella et al., 1997).660 Cell Reports 17, 660–670, October 11, 2016 ª 2016 The Authors
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sites, the signaling pathways underlying this process remain un-
clear. Studies have identified protein kinases that act as negative
regulators in controlling parasite differentiation, such as the
MAPK5, ZFK, and TbTOR4 kinases (Mony and Matthews,
2015). In addition, proteins associatedwith cAMP/AMPprocess-
ing and purine balance may be involved, suggesting that the
AMP/ATP ratio influences a finely tuned balance between energy
consumption and differentiation processes (Barquilla et al.,
2012; Laxman et al., 2006; Mony et al., 2014).
Most cells operate as self-sustaining systems, in which energy
balance is maintained by a complex homeostatic system
involving signaling pathways and nutrient sensors at multiple
levels. In eukaryotes, the major ‘‘nutrient and energy’’ proteins
are the target of rapamycin (TOR) and AMP-activated kinase
(AMPK). Both kinases regulate the balance between catabolic
and anabolic processes in accordance with cell requirements
(Dunlop and Tee, 2013; Xu et al., 2012). T. brucei has an exten-
sive family of TOR kinases, including TbTOR1 and TbTOR2,
that are functional orthologs of yeast TOR proteins and control
protein synthesis and actin polarization, respectively (Barquilla
et al., 2008). In addition, a novel TOR kinase, TbTOR4, was iden-
tified that regulates the transition to quiescence in T. brucei.
Ablation of TbTOR4 induces a molecular and biochemical
phenotype that resembles the stumpy bloodstream form, which
is pre-adapted to the insect host and to subsequent differentia-
tion into the proliferative procyclic form (Barquilla et al., 2012).
Conversely, TbTOR4 is significantly more phosphorylated in
the procyclic form, suggesting that this kinasemaintains the pro-
liferation rate of the trypanosome and changes in response to
nutritional requirements (Urbaniak et al., 2013). Furthermore,
TbTOR4 activity is negatively regulated by AMP analogs, sug-
gesting that reduced cellular energy (i.e., a high AMP/ATP ratio)
promotes differentiation (Laxman et al., 2006; Barquilla et al.,
2012).
In most eukaryotic cells, the main energy sensor seems to be
AMPK, which senses changes in the AMP/ATP ratios during
muscle contraction, oxidative stress, and glucose starvation
(Hardie, 2007). Thus, AMPK operates as an on/off switch be-
tween energy-producing and energy-consuming metabolic pro-
cesses (Daval et al., 2006). AMPK, which is highly conserved
across eukaryotes, is a serine/threonine kinase that forms a het-
erotrimeric complex and includes a catalytic a subunit and.
creativecommons.org/licenses/by-nc-nd/4.0/).
regulatory b and g subunits. In mammals, there are two isoforms
of the a subunit, a1 and a2; two isoforms of the b subunit, b1 and
b2; and three isoforms of the g subunit, g1–g3; resulting in up to
12 possible heterotrimeric combinations (Hardie et al., 2012).
The a subunit has a kinase domain at the N terminus that is
activated in response to phosphorylation at Thr172 in the activa-
tion loop; thus, phosphorylation of this subunit is widely used as
amarker of AMPK activation (Hawley et al., 1996). Kinase activity
is triggered by several types of metabolic events that involve
increases in AMP, ADP, or Ca2+ levels; more importantly, it is
also triggered by the upstream kinase LKB1 and by CAMKKb
phosphorylation of Thr172 (Woods et al., 2005). Furthermore,
AMP binding to AMPK leads to a conformational change, mak-
ing AMPK a poorer substrate for phosphatases, and hence
increasing its phosphorylation (Davies et al., 1995).
AMPK activation can initiate a series of signaling events
that conserve energy globally by inhibiting mTOR activity (Kim
et al., 2011). Thus, AMPK becomes active under nutrient-
poor conditions and inactive under nutrient-rich conditions, the
converse of what is observed for mTOR. The mechanisms un-
derlying mTOR inhibition are either AMPK phosphorylation of
themTOR partner raptor (Gwinn et al., 2008) or AMPK phosphor-
ylation of the tumor suppressor TSC2, a negative regulator of
mTOR (Inoki et al., 2003). Accordingly, AMPK and mTOR
represent diverse yet versatile energy sensors and metabolic
regulators that regulate cell fate decisions in eukaryotes. Conse-
quently, pathogens may have evolved to manipulate these path-
ways in order to achieve optimal levels of proliferation and cell
fitness while avoiding exhaustion of host resources (Brunton
et al., 2013).
In the present study, we report the biochemical characteriza-
tion of AMPK complexes for the first time in T. brucei and
describe the function of AMPK as a novel regulator of the devel-
opment of quiescence bloodstream forms.
RESULTS
AMPK Complexes in T. brucei Contain AMPKa1 and
AMPKa2
TbTOR4activity is negatively regulatedbyAMPanalogs (Barquilla
et al., 2012); hence, AMPK may act as a sensor of AMP levels in
trypanosomes.We searched the trypanosomegenomedatabase
for orthologs of AMP-dependent kinases and found two proteins
with significant homology to yeast SNF1, which we named
TbAMPKa1 (Tb927.10.5310) and TbAMPKa2 (Tb927.3.4560).
We also identified TbAMPKb (Tb927.8.2450) and TbAMPKg
(Tb927.10.3700) regulatory subunit orthologs. To investigate
whether these proteins formed a complex in T. brucei, as
described for other eukaryotes,we used epitope-tagged versions
of the TbAMPKa1 and TbAMPKb subunits (tagged with HA and
protein C, respectively) and performed affinity purification fol-
lowed by liquid chromatography-tandem mass spectrometry
proteomic analyses. These analyses allowed us to identify inde-
pendent complexes, since the TbAMPKa1 subunit is associated
with the common subunits TbAMPKb and TbAMPKg, whereas
the TbAMPKb subunit is associated with both TbAMPKa1 and
TbAMPa2 in addition to TbAMPKg (Figures 1A and 1B). Interest-
ingly, proteomics suggests additional proteins might interactwith the TbAMPK core complexes that were previously identified
as readouts of the AMPK pathway in other eukaryotes. Among
these were some involved in crucial metabolic processes such
as glycolysis (GSK3, hexokinase, and phosphofructokinase),
and reactive oxygen species (ROS) metabolism (trypanothione
peroxidase system TRYP1, TRYP2, TxN1a, and thioredoxin)
(Brunton et al., 2013; Wu and Wei, 2012). Taken together, these
results suggest that AMPK in T. brucei is represented by structur-
ally and functionally conserved TbAMPKa1 and TbAMPKa2
complexes.
Functional Analysis of T. brucei AMPKs
The proteomic analysis identified TbAMPKa1 and TbAMPKa2 as
conservedkinases that co-purifiedwith TbAMPKb andTbAMPKg
(Figure 1A and 1B). Although the metazoan TbAMPKa1 and
TbAMPKa2 proteins have very similar molecular weights, the
trypanosome AMPKs are predicted as 80.6 kDa (TbAMPKa1)
and 70.6 kDa (TbAMPKa2) in size. Western blot analysis, using
an anti-phospho-Thr172 antibody identified two bands corre-
sponding to these sizes (Figure 1B). The anti-phospho-Thr172
antibody was developed against the AMPK N-terminal region,
which is conserved between human and trypanosome AMPKa
(Figure 1C). To confirm that TbAMPKa1 and TbAMPKa2 were
distinct proteins, we conducted RNAi experiments that depleted
each kinase separately or both simultaneously.Western blot anal-
ysis demonstrated that the signal corresponding to the 80-kDa
protein was reduced by RNAi targeting TbAMPKa1, whereas
the lower 70-kDa band corresponding to TbAMPKa2 was
reduced by RNAi targeting TbAMPKa2 (Figure 1D). Both signals
were reduced by the RNAi targeting both kinases. These results
indicate that the anti-phospho-Thr172 antibody recognized both
trypanosome kinases, TbAMPKa1 and TbAMPKa2. They also
confirmed thespecificityof theantibody, since the signalobtained
bywestern blot analysis was reduced whenwe analyzed extracts
in the absence of a phosphatase inhibitor cocktail (Figure 1D).
TbAMPKa1 Activation by AMP Analogs
We next investigated whether an allosteric activator of AMPK,
which mimics AMP, could activate TbAMPKs. Bloodstream cells
were treated in culture for 18 hr with 1 mM 8-pCPT-20-O-Me-50-
AMP at different points during logarithmic growth. Western
blot analysis using the anti-phospho-Thr172 AMPK antibody
showed clear upregulation of TbAMPKa1 phosphorylation, but
the TbAMPKa2 level was unaffected (Figure 2A). Increased
TbAMPKa1 phosphorylation did not alter protein levels of
HA-TbAMPKa1 (Figure 2B).
We also investigated the kinetics of TbAMPKa1 activation by
the AMPanalog. TbAMPKa1 activation occurred in a time-depen-
dent manner (Figure 2C). In addition, TbTOR4 protein levels were
reduced after 24 hr of treatment, as described previously (Bar-
quilla et al., 2012). TbAMPKa1 showed a minor increase in phos-
phorylation due to parasite growth; however, this activation did
not obviously affect TbTOR4 expression levels (Figure 2D).
TbAMPKa1 Activation Is Associated with Development
of a Stumpy-like Form
During T. brucei infection, proliferation of the bloodstream form
is reduced by differentiation to a quiescent stumpy form. ThisCell Reports 17, 660–670, October 11, 2016 661
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Figure 1. Characterization of AMPK Complexes in Trypanosoma brucei
(A) Proteomic analyses identify TbAMPK complexes and associated proteins. Proteins in tables were selected either by a high number of hits (peptides identified
by MS/MS) or by a previously described functional or biochemical association with AMPK in other eukaryotes. Two independent affinity purifications using the
catalytic subunit TbAMPKa1 or the regulatory subunit TbAMPKb suggest that AMPKs form two independent and conserved complexes. Proteins present
significantly in the negative control sample proteins were subtracted from the lists (see Table S1 for the full list of co-purified proteins and control sample).
(B) Co-IP of protein C-TbAMPKb reveals that two AMPK catalytic a subunits (TbAMPKa1 and TbAMPKa2) bind to AMPKb. The anti-phospho-Thr172 AMPK
antibody recognizes both TbAMPKa subunits.
(C) Schematic representation of the conserved regions of the TbAMPK orthologs. The TbAMPKa1 and TbAMPKa2 kinase domains have the conserved activation
loop described in other organisms.
(D) RNAi targeting TbAMPKa1 and TbAMPKa2 downregulates these proteins, and this downregulation can monitored by western blot analysis using an anti-
phospho-AMPKa (Thr172) antibody. To investigate the phosphospecificity of this antibody, protein extracts were incubated with or without a phosphatase in-
hibitor cocktail (PhosSTOP; Roche)is presumed to prevent prevents exhaustion of host resources
and pre-adapts the parasite for transition to the insect vector
(Fenn and Matthews, 2007). Stumpy differentiation is thought
to occur via a quorum-sensing mechanism in response to a
chemically uncharacterized extracellular factor, or SIF. Labora-
tory-adapted monomorphic strains are insensitive to SIF and
unable to fully differentiate into the quiescent stumpy form
(Turner et al., 1995). However, AMP and hydrolysable analogs
of cAMP, but not hydrolysis-resistant analogs, do induce a
stumpy-like quiescent form in monomorphic strains (Barquilla
et al., 2012; Laxman et al., 2006; Vassella et al., 1997). As treat-
ment with the AMP analog increases TbAMPKa1 phosphoryla-
tion (Figure 2), we investigated whether TbAMPKa1 activation
paralleled the differentiation of the monomorphic strain to the
stumpy-like form.
Differentiation to the stumpy form is characterized by specific
changes in the T. brucei transcriptome. Thus, we examined the662 Cell Reports 17, 660–670, October 11, 2016effect of TbAMPKa1 activation by the AMP analog on gene
expression using qRT-PCR of transcripts that are selectively
regulated in the stumpy form (Kabani et al., 2009). We compared
transcript profiles in AMP analog-treated and untreated cells
(Figure 3A). Levels of HpHbR and THT-1 mRNA decreased after
AMP treatment, whereas levels of protein associated with differ-
entiation 1 and 2 (PAD1 and PAD2) mRNAs significantly
increased, as described previously (Kabani et al., 2009). Interest-
ingly, AMP treatment also reduced the level of variant surface
glycoprotein (VSG) mRNA derived from the active locus.
Western blot analysis using the anti-phospho-Thr172 antibody
showed that, in T. brucei cells treated with either hydrolyzable
cAMPor with AMP analogs, TbAMPKa1 expression was upregu-
lated, whereas TbAMPKa2 expression remained unaffected
(Figure 3B). Furthermore, expression of VSG, the surface protein
characteristic of the bloodstream form, was clearly reduced,
whereas control protein levels were unaltered. These data
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Figure 2. AMPKa1 Kinase Is Activated in Response to Treatment
with Nucleotide Analogs
(A) Bloodstream parasites were left untreated or were treated with 1 mM AMP
analog (AMP an.) (8-pCPT-20-O-Me-50-AMP) for 18 hr. The level of phos-
phorylated-TbAMPKa1 increased in treated cells compared to non-treated
cells. The samples were collected in the early and mid-logarithmic phases of
parasite growth to avoid a possible density-response effect due to AMPK
activation.
(B) As in (A), parasites were treated with 1 mM AMP analog (8-pCPT-20-O-Me-
50-AMP) for 18 hr and collected for western blot analysis. The level of
HA-tagged TbAMPKa1 was not altered after treatment with AMP analog
(8-pCPT-20-O-Me-50-AMP).
(C) TbAMPKa1 activation in AMP analog-treated parasites increases in a time-
dependent manner. TbTOR4 expression was reduced in parallel with the in-
crease in TbAMPKa1 phosphorylation.
(D) TbAMPKa1 phosphorylation depends on parasite density. Unlike the
increase due to allosteric activation, this increase does not affect TbTOR4
expression. One representative western blot is shown; results were repeated
two times, and some individual conditions were repeated numerous additional
times.suggest that AMP treatment triggers differentiation into the
stumpy form, a form in which VSG expression is downregulated,
as previously described (Amiguet-Vercher et al., 2004).
In order to further investigate the role of TbAMPKa1 in the
regulation of the expression of stumpy-associated genes, we
used a truncated version of the TbAMPKa1 kinase that is consti-
tutively active (CA) (Um et al., 2013). Expressing CA-HA-
TbAMPKa1 elicited changes in gene expression that were similar
to those following activation with an AMP analog (Figures 3C and
3D), confirming that TbAMPKa1 has a positive role in activating
the parasite differentiation process to the quiescent form.
To investigate whether the observed AMP-mediated mRNA
changes were dependent on TbAMPK, we used the AMP analog
to treat cell lines in which the TbAMPKa1 and TbAMPKa2
kinases were depleted by RNAi. Cells depleted of each protein
separately did not show significant changes in proliferation (Fig-
ure S1), nor did AMP treatment induce a stumpy-like phenotype,
as shown previously (Barquilla et al., 2012; Laxman et al.,
2006). Importantly, however, when both the TbAMPKa1 and
TbAMPKa2 subunits were depleted using RNAi, the parasite
showed resistance to AMP-induced growth inhibition, suggest-
ing that the TbAMPK complex is the major target of this com-pound (Figure 4A). Double-RNAi-treated cells did not show the
same pattern of stumpy-specific mRNAs induced by AMP as
in untreated cells (Figure 3A), suggesting that TbAMPKa1/2 are
required for the transcription remodeling (Figure 4B). These find-
ings indicate that TbAMPKa1/2 are involved in positive regula-
tion of differentiation into the stumpy-like trypanosome form.
Next, we investigated whether TbAMPKa1 responds to the
AMP analog treatment. Accordingly, we utilized a purified HA-
TbAMPKa1 complex to perform a series of in vitro phosphoryla-
tion assays in the presence of [g-32P]ATP and the SAMSpeptide,
an AMPK substrate (Davies et al., 1989). In vitro phosphorylation
assays using HA-TbAMPKa1 purified from cells showed moder-
ate phosphorylation activity under control conditions. However,
after cell treatment with 10 mM AMP analog for 30 min, purified
HA-TbAMPKa1 showed a significant increase in specific activity
(in picomoles per minute) over non-AMP-treated cells (Fig-
ure 4C). These data suggest that AMP activates TbAMPKa1.
Nevertheless, additional analysis using an AMPK-specific inhib-
itor was required to rule out the possibility that the signal that was
detected was due to a contaminating kinase. Cells treated with
AMP were incubated with compound C, a well-known inhibitor
of AMPK (Vucicevic et al., 2011). In vitro phosphorylation assays
showed that compound C abolished the effects of the AMP
analog (Figure 4C). To further analyze the effects of this inhibitor,
we pre-treated parasites for 4 hr with compound C and then
treated themwith AMP for 18 hr. Parasites pre-treated with com-
poundC showed resistance to the AMP analog growth inhibition,
confirming the specificity of AMP and compound C in targeting
the AMPK kinase (Figure 4D). Taken together, our results sug-
gest that AMP activates TbAMPKa1 and that compound C is
an effective inhibitor of the kinase activity of TbAMPKa1.
AMPKa1 Is Regulated during the Differentiation of
Pleomorphic Cells
At high parasitemia in the mammalian host, pleomorphic
trypanosomes undergo the slender-to-stumpy differentiation
process. Stumpy-like forms generated by AMP treatment of
lab-adapted monomorphic strains show TbAMPKa1 activation
in vitro (Figure 3). However, we considered it important to inves-
tigate this in wild-type pleomorphic trypanosomes during infec-
tion of mice to confirm biological relevance. To address this, we
investigated whether TbAMPKa1 activation occurs during natu-
ral infection by isolating pleomorphic AnTat 1.1 bloodstream
trypanosomes at different times during the course of mouse
infection. During the course of an infection, the slender pro-
liferative trypanosomes are sensitive to mild acidic pH 5.5 con-
ditions, whereas the quiescent stumpy form is fully resistant,
presumed as part of pre-adaptation to the insect vector mid-
gut (Nolan et al., 2000). To monitor the degree of differentiation
to the stumpy form, we isolated parasites from mice and
analyzed cell resistance to mildly acidic pH. Western blot anal-
ysis during developmental differentiation clearly showed that
TbAMPKa1 is not activated in the proliferative slender form,
whereas robust TbAMPKa1 phosphorylation is detected at the
initial stages of differentiation, suggesting that TbAMPKa1 acti-
vation occurs very early during stumpy differentiation and is
maintained throughout the process (Figure 5A). Interestingly,
when the parasites developed a full stumpy form differentiationCell Reports 17, 660–670, October 11, 2016 663
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Figure 3. Activation of AMPKa1 Kinase Trig-
gers Remodeling of the Quiescent Stumpy
Transcriptome in Bloodstream T. brucei
(A) Allosteric activation of TbAMPKa1 by 1 mM AMP
analog (8-pCPT-20-O-Me-50-AMP) induces similar
transcriptome changes that occur during slender
to stumpy differentiation. mRNA analyzed by RT-
qPCR in cells treated with 1 mM AMP analog for
18 hr and untreated control include genes previ-
ously associated with stumpy differentiation; PAD1,
PAD2, THT-1, HpHbR, myosin (MYO), VSG221
(MITat 1.2/VSG2), and procyclin. The gene expres-
sion levels are represented as the fold changes
compared to untreated cells using comparative
cycle threshold (Ct) calculations, with two internal
standards; the PI3K-related protein (Tb927.2.2260)
and the control (C1) protein (Tb10.389.0540).
(B) Activation of AMPK using hydrolysable analogs
of cyclic-AMP (cAMP) and 8-pCPT-20-O-Me-50-
AMP (AMP an.) decreased the expression level of
the VSG 221 protein as detected by western blot
analysis.
(C) Constitutively active (CA) HA-TbAMPKa1 lack-
ing a regulatory interaction domain was tagged with
the HA epitope and expressed in T. brucei. Two
independent clones (A and B) were analyzed by
western blot using anti-phospho-AMPKa (Thr172)
antibody and anti-HA monoclonal antibody to
detect the CA-HA-AMPK. CA-HA-AMPK expression seems to increase the basal phosphorylation level of TbAMPKa1.
(D) Expression of CA-HA-AMPK induced gene expression changes characteristic of the stumpy form. Constitutively active AMPK expression results in a
transcription remodeling similar to that induced by treatment with an AMP analog (A).
All data are reported as the mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.0001 using the two-tailed t test for paired observations.(100% resistance to pH 5.5), TbAMPKa1 activation returned
to the initial low levels. Finally, when the parasites develop
into the proliferative procyclic insect form, which involves drastic
metabolic changes, TbAMPKa1 phosphorylation increased
dramatically. In addition, TbTOR4 decreased at the protein level
during stumpy differentiation (Figure 5A), similar to the decrease
observed after AMP treatment of the monomorphic strain (Fig-
ure 2C). Therefore, TbAMPKa1 is activated not only in in vitro-
generated stumpy-like cells but also in wild-type pleomorphic
forms (Figure 5A). These results suggest that TbAMPKa1 acti-
vation is indeed associated with proliferative bloodstream differ-
entiation to quiescent stumpy forms that are pre-adapted to
the insect stage where TbAMPKa1 is active again.
AMPKa1 Inhibition Reduces Differentiation to the
Quiescent Stumpy Form during Infection in Mice
In vivo differentiation to the stumpy form correlates with
TbAMPKa1 activation in pleomorphic trypanosomes (Figure 5A).
Thus, we sought to investigate whether inhibition of TbAMPKa1
could halt stumpy form development during in vivo infection.
In vitro phosphorylation assays showed that compound C in-
hibited TbAMPKa1 activity (Figure 4C). Thus, we decided to treat
infected mice with two concentrations of compound C and then
analyze parasitemia at different time points during the infection.
Figure 5B shows that more parasites were isolated from mice
treated with compound C, suggesting a delay in quiescence
and continued proliferation. Furthermore, we isolated parasites
from infected mice treated with different amounts of compound
C and analyzed the cellular phenotype. First, living cells treated664 Cell Reports 17, 660–670, October 11, 2016with compound C moved faster than controls (Movies S1 and
S2), and the classic stumpymorphology decreased by 50% (Fig-
ure 5C). Second, when TbAMPKa1was inhibitedwith compound
C, the cells were less resistant to mildly acidic pH, contrary to
what occurs in untreated cells with a stumpy phenotype (Fig-
ure 5D). Finally, we isolated mRNA from these cells and inves-
tigated changes in the expression levels of the PAD family
mRNAs, considered stumpy marker genes. Figure 5E shows
that PAD1 and PAD2 mRNA expression was reduced in para-
sites isolated from mice treated with compound C compared
with expression in parasites isolated from untreated mice.
Furthermore, immunofluorescence analysis of PAD1 protein
expression in compound C-treated cells showed clear downre-
gulation (Figure S2). Collectively, these results suggesting that
inhibition of TbAMPKa1 activity by compound C reduced differ-
entiation to the stumpy form. Furthermore, TbAMPKa1 phos-
phorylation correlates with a decrease in TbTOR4 expression.
Upstream Regulators of TbAMPKa1 Activation
Next, we sought to identify possible activators of TbAMPKa1.
The proteomic analysis identified proteins that are well-known
regulators of TbAMPKa1 activity in other eukaryotes, such as
GSK3, as well as proteins involved in oxidative metabolism (Fig-
ure 1A). In addition to its role in regulating glycogen synthase,
GSK3b is implicated in other aspects of glucose homeostasis
in mammalian cells (Suzuki et al., 2013). Notably, glucose ho-
meostasis is a vital feature of energy metabolism in the blood-
stream. Co-immunoprecipitation (IP) experiments that used
HA-epitope tagged TbGSK3 and protein C-tagged TbAMPKb
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Figure 4. Cells Become Resistant to AMP Treatment upon Down-
regulation of the AMPKa1/2 Kinases
(A) Depletion of the AMPKa1/2 subunits using RNAi counteracts the growth
defect caused by AMP treatment of bloodstream cells. After 48 hr of AMPKa1/
2 depletion using RNAi, T. brucei were treated for 18 hr with an AMP analog.
(B) Total RNAwas purified from the cells shown in (A), and the expression of the
PAD1, PAD2, and VSG 221 mRNA was quantified at the transcriptional level.
The regulation of these canonical differentiation genes was compromised by
kinase knockdown using RNAi.
(C) AMPKa1 can phosphorylate the SAMS peptide in vitro in an AMP-
dependent manner. Bloodstream parasites were incubated with or without
10 mMAMP analog (8-pCPT-20-O-Me-50-AMP) for 30min. HA-TbAMPKa1was
immunoprecipitated with an anti-HA agarose matrix. AMPK activity was as-
sayed by [32P]ATP incorporation into the SAMS peptide. The use of compound
C (CC) abolished the activation of the kinase.
(D) Parasites pretreated with compound C do not show the growth defect
phenotype induced by the AMP analog (8-pCPT-20-O-Me-50-AMP). The par-
asites were pretreated with 0.25 mM compound C for 4 hr and then incubated
with 1 mM AMP analog for 18 hr.
All data are reported as the mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p <
0.0001 using the two-tailed t test for paired observations.confirmed the interaction (Figure S3A). Knockdown of TbGSK3
using RNAi showed increased TbAMPKa1 phosphorylation as
detected by western blot analysis (Figure S3B). In addition,
qRT-PCR analysis suggested that TbGSK3 depletion results
in gene expression changes similar to those induced by
TbAMPKa1 activation (Figure S3C). These results suggest
that the functional interaction between GSK3 and AMPKb is
conserved in trypanosomes.
A bona fide developmental marker for the stumpy cell type is
mitochondrial activation (Fenn and Matthews, 2007), suggesting
that oxidative stress occurs during parasite differentiation. The
AMPK pathway is an important signaling cascade involved in
sensing the oxidative response (Duarte et al., 2015), whereby
an increase in intracellular ROS induced AMPK activation (Zmi-
jewski et al., 2010). To investigate this possibility, we treated
parasites with H2O2 in a time course to mimic ROS increase.
TbAMPKa1 phosphorylation gradually increased in response tothe addition of exogenous H2O2, reaching a peak after 1 hr of
treatment and decreasing later (Figure 6A). The dynamic regula-
tion of AMPK phosphorylation suggests this kinase is function-
ally involved in T. brucei oxidative metabolism.
To further characterize the function of AMPKs in oxidative
stress,we treatedparasiteswithH2O2after depletingTbAMPKa1,
TbAMPKa2, or both using RNAi. In the absence of TbAMPKa1,
the cells failed to efficiently metabolize H2O2, suggesting that
TbAMPKa1 has an antioxidant function in trypanosomes, as
in other eukaryotes (Figure 6B). Interestingly, depletion of
TbAMPKa2, which increases the phosphorylation of TbAMPKa1
likely as a compensation mechanism, protected parasites from
oxidative stress (Figure 6B). To confirm a putative antioxidant
function, we activated TbAMPKa1 with the AMP analog and
found a dramatic reduction of intracellular ROS in cells treated
with H2O2 (Figure 6C). These results altogether suggest that
oxidative stress induces TbAMPKa1 phosphorylation, which in
turn functions as a feedback regulator for ROS internal levels.
To investigate whether a ROS increase is associated with dif-
ferentiation to the stumpy form, we analyzed by RT-qPCR the
mRNA levels for the differentiation markers PAD1 and PAD2 in
cells treated with 25 mM H2O2 (Figure 6D). A significant increase
of the PAD expression after only 20- to 30-min treatment was de-
tected (Figure 6D), concomitant with the AMPK phosphorylation
(Figure 6A).
An important question, however, is whether oxidative stress
occurs naturally during in vivo differentiation of a wild-type
pleomorphic strain. Bloodstream pleomorphic trypanosomes
undergo differentiation from the proliferative to the stumpy
form very efficiently throughout infection of mice. Thus, we
analyzed intracellular ROS levels of parasites isolated from
mice at days 3, 4, and 5 post-infection. Significant levels of
intracellular ROS were detected early during infection (day
3), when a low percentage of stumpy cells were detected
(8.05% PAD1 positive; Figure 6E). However, parasites isolated
on day 5 post-infection, with 97% stumpy cells, had dramat-
ically reduced ROS levels. Unfortunately, we were unable
to analyze ROS levels at day 3 due to low parasitemia.
Notwithstanding, proliferative monomorphic strain displayed
lower ROS levels that the pre-stumpy cells from day 3. These
data show that slender cells committed to stumpy differentia-
tion generate higher levels of intracellular ROS than stumpy
cells (Figure 6E), suggesting that active TbAMPKa1 in pre-
stumpy forms is involved in ROS detoxification (Figures 6B
and 6E).
We next investigated possible cross talk between the TbTOR4
and TbAMPKa1 pathways. Allosteric activation of TbAMPKa1 by
the AMP analog leads to TbTOR4 downregulation detected
by western bot analysis (Figure 2C). Thus, we investigated
whether TbAMPKa1 activity is required in cells where TbTOR4
was depleted. Inhibition of TbAMPKa1 activity by compound C
treatment of cells depleted of TbTOR4 did not affect the
developmental gene expression program (Figure S4). Next, we
generated cell lines where both TbTOR4 and TbAMPKa1 were
depleted by double inducible RNAi. Again, gene expression
analysis of stumpy-specific marker genes showed no significant
differences compared with the single TbTOR4 depletion (Fig-
ure S5). Thus, the developmental gene expression programCell Reports 17, 660–670, October 11, 2016 665
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Figure 5. AMPKa1 Inactivation Impairs the
Differentiation of T. brucei to the Quiescent
Stumpy Form during Infection in Mice
(A) Western blot analysis shows AMPKa1 regulation
during differentiation from the proliferative slender
(SL) form to the quiescent stumpy form in pleo-
morphic cells grown in vivo. One representative
western blot is shown. Experiments were repeated
three times.
(B) Inhibition of AMPK by compound C increases
proliferation in parasites. The mice were treated
daily intraperitoneal with 1.5 or 4.5 mg/kg of com-
pound C 72 hr after inoculation with the AnTat 1.1
pleomorphic strain.
(C) Analysis of the distribution of the slender
versus stumpy form showed that 50% of the
compound C-treated parasites remained slender
and were less resistant to pH mild-to-low acidic
fluctuations.
(D) In contrast, the non-treated parasites differen-
tiated to the stumpy form.
(E) Stumpy markers such as PAD1 and PAD2 were
downregulated after inhibition of TbAMPK with
compoundC. The gene expression levels are shown
as the fold changes compared to untreated cells
based on comparative cycle threshold (Ct) calcu-
lations using the PI3K-related gene as control. Genes analyzed: PAD1, PAD2, THT-1, HpHbR, and control (C1) protein.
The error bars in (B) and (C) were calculated from independent mouse infections (three per mouse per group). All data are reported as the mean ± SEM (n = 3).
*p < 0.05; **p < 0.01; ***p < 0.0001 using the two-tailed t test for paired observations.triggered by TbTOR4 depletion occurs independently of
TbAMPKa1 activity.
DISCUSSION
African trypanosomes need to precisely control their energy and
proliferation in order to respond to changes in the host environ-
ment and to protect the viability of the host. Such control is
fundamental to the host-parasite transition and to the efficiency
of transmission. T. bruceimaintains an integral link between cell
cycle regulation and differentiation during its life cycle, which in-
volves the response to parasite density and SIF. Here, we report
a novel function for TbAMPK as a key factor in the regulation
of differentiation from the proliferative to stumpy forms, which
suggests a link between metabolic activity, differentiation, and
control of parasitemia.
The function of the TbAMPKa subunits in trypanosomes and
the structure of possible TbAMPK complexes were previously
totally unknown. However, depletion of the TbAMPK regulatory
subunits TbAMPKb and TbAMPKg does induce changes in the
expression of surface proteins in the insect (procyclic) stage of
the parasite (Clemmens et al., 2009). Here, we first characterized
the composition of the AMPK core complexes in T. brucei and
found two a subunits that associate to form two distinct com-
plexes together with the common TbAMPKb and TbAMPKg
subunits. We used the name TbAMPKa1 (Tb927.10.5310)
because this protein responds to an allosteric activator that
mimics AMP and because it functions in metabolic regulation
as described in other organisms (Aymerich et al., 2006; Gowans
et al., 2013).
Proteomic analysis of the AMPK complex and co-IP experi-
ments suggests that trypanosome AMPK also interacts with666 Cell Reports 17, 660–670, October 11, 2016TbGSK3, a kinase involved in glucose metabolism, and is asso-
ciated with this pathway in other eukaryotes (Hardie et al., 2012).
GSK3b inhibits AMPK activity by interacting with the AMPKb
regulatory subunit in a stable manner (Suzuki et al., 2013), and
our evidence suggests a similar mechanism via association
of TbGSK with the TbAMPK complex (Figure S3). In addition,
trypanosome GSK3 depletion induced a similar stumpy pheno-
type as TbAMPKa1 activation, which suggests that TbGSK is a
negative regulator of TbAMPK in trypanosomes. These data
suggest that the AMPK/GSK interaction and control mechanism
is conserved in T. brucei and that this acts to regulate energy
balance metabolism.
In order to assess the relative contribution of AMPK activation
to parasite metabolism, we used a highly permeable allosteric
activator tomimic AMP. Treatment with the AMP analog resulted
in a specific increase in TbAMPKa1 phosphorylation, but signifi-
cantly phosphorylation of TbAMPKa2 remained unchanged (Fig-
ure 2). In other systems, an increase in AMP alters the ATP/AMP
ratio, and this is sensed mainly by AMPK where phosphorylation
ispromotedbyupstreamkinases (Carling et al., 2012).Our obser-
vations therefore suggest that, in T. brucei, AMPKa1 is a major
player in sensing and coordinating the flux of energy in the para-
site. Interestingly, the canonical AMPK upstream kinase, the
LKB1-STRAD-MO25 complex, has yet to be described in trypa-
nosomatids, but our proteomics identified a putative candidate
that shares low but significant homology with the mammalian
LKB1 (Tb927.11.7010) catalytic domain (Table S1), suggesting
that part of this signaling pathway may also be conserved.
To compensate for fluctuations in ATP levels, AMPK regulates
a wide range of metabolic pathways to control energy fluctua-
tions and maintain cell homeostasis. The parasite avoids over-
growth in the mammalian host by developing into a quiescent
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Figure 6. AMPKa1 Is Activated in Response to Oxidative Stress
(A) AMPKa1 senses oxidative stress induced by exogenous H2O2. Cells were incubated with 25 mM hydrogen peroxide and AMPKa1 phosphorylation analyzed
bywestern blot using phospho-specific antibody at the indicated time points in minutes. The level of phosphorylated AMPKa1 oscillated in AMP analog (AMP an.)
(8-pCPT-20-O-Me-50-AMP)-treated cells compared to untreated (UT) cells.
(B) Depletion of AMPKa1 impairs ROSmetabolism. AMPK subunits were depleted by RNAi for 24 hr, and cells were subsequently incubated for 20minwith 50 mM
H2O2. Intracellular ROS was assayed by flow cytometry of oxidized CM-H2DCFDA. The effectiveness of AMPK knockdown was examined by western blot
analysis.
(C) AMPKa1 activation by AMP analog (8-pCPT-20-O-Me-50-AMP) improves oxidative metabolism by reducing intracellular ROS levels. The parasites were
incubated for 18 hr with 1–10 mM of AMP, washed, and then incubated with 100 mM H2O2 during 30 min.
(D) Hydrogen peroxide treatment of cells results in an increase of stumpy-specific gene expression. Histogram showing the relative expression of mRNAs
measured by qRT-PCR of U2, HpHbR, PAD1, and PAD2mRNAs isolated from cells treated with H2O2. The gene expression levels are shown as the fold changes
compared to untreated cells (0 min) based on comparative cycle threshold (Ct) calculations using the PI3K-related and control 1 (C1) genes as control. The error
bars were calculated from three independent experiments. All data are reported as the mean ± SEM (n = 3). *p < 0.05 and **p < 0.01 using the two-tailed t test for
paired observations.
(E) ROS fluctuation during in vivo development of parasites to the quiescence stumpy form. AnTat 1.1 pleomorphic strain was infected in mice, and intracellular
ROS levels were analyzed at day 3 to 5 post-infection. PAD1 surface expression immunofluorescence analysis of blood-isolated parasites was used to detect
stumpy form. Previous to the progression of the quiescence stumpy form, intracellular ROS levels were higher than later when stumpy differentiation is detected.
(M) Monomorphic proliferative strain growing in culture is used as control. Statistical differences were found between mice at 4 and 5 days post-infection
compared with mice at 3 days. Data represent mean ± SEM (n = 3) calculated from independent mouse infection (three per mouse per group). **p < 0.01 using the
two-tailed t test for paired observations.form (Vassella et al., 1997). In trypanosomes, TbAMPKa1 also
senses changes in cell proliferation (Figure 2D), but this revers-
ible TbAMPKa1 activation does not drive either differentiation
or TbTOR4 downregulation. TbAMPKa1 allosteric activation
(e.g., by AMP analogs) cannot be reversed and is effective in
activating the kinase, triggering differentiation to quiescence
and TbTOR4 downregulation (Figure 2C).
Activation of TbAMPKa1 promotes the initial steps of differen-
tiation of T. brucei into stumpy-like forms in strains that do not
normally fully differentiate in vitro. Activation by AMP analogs
also induces the expression of developmentally regulated genes(Figure 3), suggesting that TbAMPK can modulate gene expres-
sion in order to modulate metabolism, similar to the case in other
eukaryotes (Thomson et al., 2008). Importantly, expression of a
constitutively active form of AMPK, CA-HA-AMPK, also induced
stumpy-like differentiation (Figure 3C). In addition, inhibition of
TbAMPK function, by either compound C or RNAi, significantly
counteracted the effects of AMP on growth inhibition and the
changes to expression of stumpymarker genes. Taken together,
these results ruled out possible indirect effects of the AMP
analog and suggest that TbAMPKa1 is a central regulator within
the stumpy differentiation process.Cell Reports 17, 660–670, October 11, 2016 667
Regardless of their differential responsiveness to differen-
tiation signals, both pleomorphic and monomorphic strains
respond to nucleoside analogs, suggesting that AMP regulation
is downstream of the response to SIF (Mony and Matthews,
2015). We also analyzed TbAMPK regulation using an in vivo
model of pleomorphic parasite differentiation in mice infections.
Western blot analyses suggest that TbAMPKa1 is activated early
during stumpy differentiation, whereas TbTOR4, as a negative
regulator of differentiation, is undetectable at this time. Interest-
ingly, TbAMPKa1 was not phosphorylated once stumpy popula-
tion reached 100%, and TbTOR4 remained undetectable. These
results, together with the downregulation of TbTOR4 upon
TbAMPKa1 activation by the AMP analog (Figure 2C), suggest
that these two events are connected and that TbAMPKa1 func-
tions upstream of TbTOR4. Furthermore, the expression of
stumpy genes was triggered regardless of TbAMPKa1 function
in TbTOR4-depleted cells (Figures S4 and S5), which is consis-
tent with either TbAMPKa1 acting upstream of TbTOR4 to regu-
late the expression of stumpy-specific genes or that TbAMPKa1
and TbTOR4 are components of two parallel signaling pathways.
Although we cannot formally rule out that these two signaling
pathways operate independently, our results suggest cross
talk between these two kinases in trypanosomes.
In mammalian osteogenic differentiation, AMPK activation
drives development by inhibiting the Akt/mTOR pathway (Pan-
tovic et al., 2013). Similarly, activation of TbAMPKa1 induced
parasite differentiation. The TbAMPKa1 activation that we de-
tected during early differentiation correlates with the accumula-
tion of intracellular AMP described in T. brucei differentiation
(Graven et al., 2014). Previous results, as well as our own data,
indicate that AMP is a key molecule in stumpy differentiation in
trypanosomes. Mitochondrial activation is an important event
in T. brucei differentiation as it enables the parasite to use proline
as a new source of ATP. Although proliferative forms obtain their
metabolic energy almost entirely from glycolysis, stumpy forms
reactivate mitochondria, restoring oxidative capacity, as a
metabolic preadaptation to a different energy source (Priest
and Hajduk, 1994). Accordingly, mitochondrion activity is
considered a differentiation control point during the life cycle of
T. brucei (Timms et al., 2002).
Dependence on glycolysis to generate ATP is an unusual
metabolic aspect of T. brucei, and glycolysis is far less efficient
than oxidative metabolism, similar to the ‘‘Warburg effect’’
described in some T cells and cancer cells (Gogvadze et al.,
2010). Taken together, our results suggest that stumpy differen-
tiation is associated with oxidative stress, most likely induced
by developmental mitochondrial activation, similar to the ROS-
AMPK pathway described in cancer cells (Hart et al., 2015).
Thus, activated TbAMPKa1 in stumpy forms helps to maintain
oxidative flux during parasite development (Figure 6). In mam-
mals, AMPK has antioxidative properties (Colombo and Mon-
cada, 2009), and our results suggest that trypanosome AMPKa1
activity prevents ROS increase, because TbAMPKa1 activation
by AMP reduced intracellular ROS induced by H2O2 (Figure 6).
Interestingly, the TbAMPK core complex co-purified with thiore-
doxin and tryparedoxin peroxidase, both components of the try-
panothione peroxidase system (Diechtierow and Krauth-Siegel,
2011) (Table S1). Thus, even though this interaction has yet to668 Cell Reports 17, 660–670, October 11, 2016be confirmed by co-IP experiments, one TbAMPK readout could
be on the trypanothione peroxidase system.
Thedata presented here suggest thatT. bruceibalances its dif-
ferentiation and proliferation programs through the TbAMPKa1
pathway. Energy homeostasis and mitochondrial regulation are
known to play key roles in the transition from proliferative blood
stages to quiescent stumpy forms and the TbAMPKa1 pathway
appears as one the major regulators of these processes, coordi-
natingmultiple stimuli tomaximize the potential for transmission.
Furthermore, as AMPK is currently a major drug target for
metabolic diseases and cancer, the trypanosome pathway may
represent a novel anti-parasitic target.
EXPERIMENTAL PROCEDURES
Detailed materials and methods are provided in Supplemental Information.
Animals
Slender and stumpy forms of pleomorphic AnTat 1.1 T. brucei brucei strain
were isolated from Balb/C-mice in compliance with policies approved by the
Committee on Use and Care of Laboratory Animals of the Instituto de Parasi-
tologı´a y Biomedicina Lo´pez-Neyra, Consejo Superior de Investigaciones
Cientı´ficas (CSIC-IPBLN).
Trypanosome Strains and AMP Analogs Treatment
Throughout this study,monomorphic bloodstream Trypanosoma brucei brucei
(Lister 427) and the pleomorphic AnTAT 1.1 were used. Parasites in culture at a
low density (2 3 105 cells/ml) were incubated with 8-pCPT-20-O-Me-50-AMP
(1 mM) and 8-pCPT-20-O-Me-cAMP (10 mM) (c078 and c041; Biolog Life Sci-
ence Institute) during 18 hr. To avoid the AMPK activation caused by cell den-
sity, the control and treated cells were analyzed at the same cell density.
Slender and stumpy forms of pleomorphic AnTAT 1.1 were purified from
BALB/c mice blood (see Supplemental Information).
Phosphorylation Assay
A total of 43 109 parasites was treated or not with 10 mM 8-pCPT-20-O-Me-50-
AMP during 30 min. After immunoprecipitation of HA-AMPKa1 (see Co-immu-
noprecipitation Assays in Supplemental Information), AMPK activity in the re-
sulting immune complexes was determined by the incorporation of [g-32P]ATP
into theconsensussubstrate, thecalledSAMSpeptide (HMRSAMSGLHLVKRR)
(Abcam Biochemicals; ab120182). In brief, purified HA-AMPKa1 was resus-
pended in 40 mL of final reaction buffer that contains 103 assay buffer
(250 mM HEPES, 200 mM ATP, 2 mM AMP, 10 mM EGTA, 10 mM DTT,
50 mM MgCl2), [g-
32P]ATP, 100 mM SAMS, or 1 mM compound C (Abcam Bio-
chemicals; ab120843) and was incubated with shaking for 30 min at 37C.
The mixture was quickly pelleted and spotted into P81 Whatman paper. Un-
reacted ATP was removed washing the filter papers four to five times with 1%
phosphoric acid. After the final wash, the filters were quickly dried with ethanol
and counted in a scintillation counter. AMPK activity was calculated by phos-
photransfer and specific activity of ATP by subtracting the average counts per
minute (cpm) of the negative controls from the average cpm of AMPK samples
and dividing this number by the specific activity of the ATP.
Detection of Intracellular ROS
A total of 2 3 106 parasites was washed and resuspended in 1 ml of TBD
glucose and incubated with 2 mM cell-permeant 20,70-dichlorodihydrofluores-
cein diacetate (H2DCFDA) (Life Technologies; C6827) for 20 min at 37C.
Finally, cells were centrifuged, resuspended in TDB glucose with 4 mg/ml
propidium iodide (to discard dead cells), and immediately analyzed by flow
cytometry.
Peroxide Hydrogen Treatment
Logarithmic-phase cells were incubated with 25 mM H2O2 (diluted in miliQ
water from the 10 M stock solution; Sigma Aldrich; H1009) from 10 to
90min at 37C. Cells were collected for western blot and RT-qPCR analysis as
described in Supplemental Experimental Procedures.
AMPK Inhibition by Compound C
Monomorphic bloodstream parasites were incubated with 0.25 mMcompound
C for 4 or 24 hr at 37C. For in vivo experiments, 1.5 or 4.5 mg,kg-1 compound
C were daily intraperitoneally injected in mice 72 hr after inoculation with the
AnTat 1.1 pleomorphic strain.
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